Dermatofibrosarcoma Protuberans (DFSP) Symptoms
At a Glance
- Sample Required: Skin biopsy (punch or excisional)
- Fasting Rules: Not required
- Turnaround Time (TAT): 5–7 working days for histopathology; 7–10 days for genetic testing
- Base Cost: [Insert Current 2026 Price]
Written by: Dr. Ananya Sharma, MBBS, MD (Dermatology)
Medically Reviewed by: Dr. Rajesh Kumar, MD (Pathology)
Last Updated: February 2026
Clinical Overview of Dermatofibrosarcoma Protuberans
Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing soft tissue sarcoma arising from the dermis. It accounts for approximately 1% of all soft tissue sarcomas. DFSP is characterized by a distinctive molecular signature: a chromosomal translocation t(17;22) that fuses the COL1A1 and PDGFB genes, leading to uncontrolled cell proliferation. Early recognition is critical because surgical excision with clear margins offers a high cure rate.
Etiology and Pathogenesis
DFSP originates from fibroblasts in the dermis. The hallmark genetic alteration is the t(17;22) translocation, which creates a COL1A1-PDGFB fusion gene. This fusion leads to constitutive activation of the PDGFB signaling pathway, driving tumor growth. While the exact cause remains unknown, risk factors include prior trauma, radiation exposure, and certain genetic predispositions. DFSP is not typically inherited, but somatic mutations are present in tumor tissue.
Early Signs and Symptom Progression
DFSP often presents as an asymptomatic, indurated plaque that gradually enlarges. Early lesions may mimic a scar, birthmark, or dermatofibroma. Over months to years, the plaque may become nodular and protuberant. The following symptoms warrant dermatologic evaluation:
- Unusual Skin Patch: Reddish-brown or pink patch resembling a scar or birthmark.
- Slow-Growing Lump: A firm, rubbery nodule develops within the patch.
- Irregular Borders: Edges may be uneven or jagged.
- Size Changes: Gradual enlargement over time.
- Skin Sensitivity: Tenderness, ulceration, or easy bleeding.
If any of these signs persist for more than two weeks, consult a dermatologist promptly.
Diagnostic Modalities and Genetic Testing
Accurate diagnosis of DFSP requires histopathological examination and, in ambiguous cases, molecular confirmation. The following table summarizes available diagnostic tests:
| Test | Purpose | Turnaround Time |
|---|---|---|
| Histopathology (H&E) | Identifies storiform pattern and cellularity | 5–7 days |
| Immunohistochemistry (CD34) | Confirms CD34 positivity typical of DFSP | 5–7 days |
| FISH for t(17;22) | Detects COL1A1-PDGFB fusion | 7–10 days |
| RT-PCR / NGS | Molecular confirmation of fusion transcript | 10–14 days |
At DNA Labs India, we offer comprehensive histopathology and molecular testing for DFSP. Our ISO 9001 certified laboratory ensures accurate and timely results.
Treatment and Prognosis
The standard treatment is wide local excision with clear margins. Mohs micrographic surgery is increasingly used for optimal margin control. In cases where surgical margins are positive or tumor is unresectable, targeted therapy with imatinib (a PDGFB inhibitor) may be considered. With early detection and complete excision, the 5-year recurrence-free survival exceeds 95%. Regular follow-up is essential due to a small risk of late recurrence.
Proactive Skin Health Measures
While DFSP is not directly preventable, general skin health practices can aid early detection:
- Sun Protection: Use SPF 30+ sunscreen and limit UV exposure.
- Skin Self-Exams: Monthly self-examination to identify new or changing lesions.
- Regular Dermatologist Visits: Especially if you have a family history of skin cancer or prior skin conditions.
When to Consult a Specialist
If you notice any persistent skin lesion that changes in size, color, or texture, or if a previously stable scar becomes raised or tender, seek dermatologic evaluation. Early diagnosis is the cornerstone of successful management.